We are live on ! Find out more
TVTX icon

Travere Therapeutics
TVTX

131 hedge funds and large institutions have $611M invested in Travere Therapeutics in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $516M → $611M (+$94.5M)

9% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 43

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

1% more funds holding

Funds holding: 130 → 131 (+1)

3.46% less ownership

Funds ownership: 103.6% → 100.14% (-3.5%)

74% less call options, than puts

Call options by funds: $668K | Put options by funds: $2.56M

Holders
131
Holders Change
+1
Holders Change %
+0.77%
% of All Funds
2.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
47
Reduced
43
Closed
20
Calls
$668K
Puts
$2.56M
Net Calls
-$1.89M
Net Calls Change
+$647K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$15.4M
2
BlackRock
BlackRock
New York
+$5.16M
3
Macquarie Group
Macquarie Group
Australia
+$4.96M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.81M
5
RCM
RA Capital Management
Massachusetts
+$3.38M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$20.2M
2
SCM
Scopia Capital Management
New York
-$15.4M
3
BC
Broadfin Capital
New York
-$7.08M
4
State Street
State Street
Massachusetts
-$5.3M
5
PA
Perceptive Advisors
New York
-$4.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.84M +$39.3K +3,076 +0.9%
SFM
27
Sphera Funds Management
Israel
$4.51M -$164K -12,822 -4%
WP
28
Woodline Partners
California
$4M +$3.59M +281,423 New
GKIM
29
GW&K Investment Management
Massachusetts
$2.7M -$180K -14,103 -7%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.65M +$79.3K +6,208 +3%
ORI
31
Oak Ridge Investments
Illinois
$2.56M -$458K -35,825 -17%
DS
32
DRW Securities
Illinois
$2.56M – – –
Axa
33
Axa
France
$2.35M – – –
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$2.34M +$222K +17,344 +12%
AI
35
Atom Investors
Texas
$2.13M -$917K -71,787 -32%
LOAMU
36
Lombard Odier Asset Management (USA)
New York
$2.13M -$319K -25,000 -14%
SSA
37
Schonfeld Strategic Advisors
New York
$2.01M +$1.81M +141,489 New
Goldman Sachs
38
Goldman Sachs
New York
$1.78M +$842K +65,934 +111%
OAM
39
Oxford Asset Management
United Kingdom
$1.47M +$1.15M +90,067 +686%
BIM
40
Bogle Investment Management
Massachusetts
$1.4M +$1.26M +98,796 New
Tudor Investment Corp
41
Tudor Investment Corp
Connecticut
$1.38M -$17.5K -1,370 -1%
California Public Employees Retirement System
42
California Public Employees Retirement System
California
$1.32M +$248K +19,400 +26%
SIM
43
Spark Investment Management
New York
$1.32M – – –
WG
44
Winton Group
United Kingdom
$1.22M +$1.1M +86,156 New
Morgan Stanley
45
Morgan Stanley
New York
$1.19M +$538K +42,130 +102%
Ameriprise
46
Ameriprise
Minnesota
$1.18M +$314K +24,579 +42%
Russell Investments Group
47
Russell Investments Group
United Kingdom
$1.17M +$738K +57,746 +234%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$1.16M +$98.8K +7,734 +10%
MSL
49
Mackay Shields LLC
New York
$1.14M +$54.9K +4,300 +6%
Barclays
50
Barclays
United Kingdom
$1.07M +$584K +45,744 +156%
1
2
3 4 5

TVTX Hedge Fund Activity: Q4 2019 in Review

131 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2019, worth a combined $611M — up 18% from $516M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new TVTX positions and 20 closed out — a net gain of 1 holder — while 47 added to existing stakes and 43 trimmed.

The largest buyer was Millennium Management, adding an estimated $15.4M. The largest seller was Great Point Partners, exiting entirely with an estimated $20.2M sold.

  • 131 institutional investors held Travere Therapeutics (TVTX) as of Q4 2019, up from 130 in Q3 2019.
  • Funds reported $611M of Travere Therapeutics stock for Q4 2019, up 18% quarter-over-quarter.
  • 21 funds opened new Travere Therapeutics positions in Q4 2019 and 20 closed out, a net change of +1 holder.
  • The largest Travere Therapeutics buyer in Q4 2019 was Millennium Management, an estimated $15.4M added.
  • The largest Travere Therapeutics seller in Q4 2019 was Great Point Partners, an estimated $20.2M sold.

Based on aggregated 13F filings for Q4 2019.